Gonadorelin
GnRH, Luteinizing Hormone-Releasing Hormone, LHRH, Factrel
A synthetic decapeptide analog of GnRH that stimulates the pituitary gland to release FSH and LH, aiding in reproductive hormone regulation and fertility treatments.
Terminated
PHASE3
NCT00066807
Premenopausal Endocrine Responsive Chemotherapy Trial
ETOP IBCSG Partners Foundation
INTERVENTIONAL
Updated Dec 15, 2025
Recruiting
PHASE2
NCT05594095
SNF Platform Study of HR+/ HER2-advanced Breast Cancer
Fudan University
INTERVENTIONAL
Updated Dec 15, 2025
Completed
NCT03656211
Fertility After Diagnosis and Management of Acquired Uterine Arteriovenous Malformation
Rennes University Hospital
OBSERVATIONAL
Updated Dec 15, 2025
Active Not Recruiting
PHASE3
NCT01957436
A Phase III Study for Patients With Metastatic Hormone-naïve Prostate Cancer
UNICANCER
INTERVENTIONAL
Updated Dec 15, 2025
Recruiting
PHASE2
NCT04812366
Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer
University of British Columbia
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE3
NCT00427245
Goserelin in Preventing Early Menopause in Premenopausal Women Undergoing Chemotherapy for Stage I, Stage II, or Stage III Breast Cancer
Anglo Celtic Cooperative Oncology Group
INTERVENTIONAL
Updated Dec 15, 2025
Unknown
NA
NCT04139629
Cohort Study Investigating the Association Between Antichlamydial Antibody Positivity and ART Outcomes in Women With TFI
D.O. Ott Research Institute of Obstetrics, Gynecology, and Reproductology
INTERVENTIONAL
Updated Dec 15, 2025
Unknown
PHASE2
NCT01266213
Fulvestrant (F)/Goserelin (G) vs Anastrozole (A)/G vs G for Premenopausal Women
Samsung Medical Center
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE3
NCT02143713
Global Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Women With Moderate to Severe Endometriosis-associated Pain
AbbVie
INTERVENTIONAL
Updated Dec 15, 2025
Active Not Recruiting
PHASE3
NCT01809691
S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer
SWOG Cancer Research Network
INTERVENTIONAL
Updated Dec 15, 2025
Unknown
NA
NCT05632731
Comparison of Clinical Outcomes in Fresh Cycle With Single Blastocyst Stage and Double Cleavage-stage Embryos: a Single-center, Non-blind, Randomized Controlled Study
Women's Hospital School Of Medicine Zhejiang University
INTERVENTIONAL
Updated Dec 15, 2025
Unknown
PHASE4
NCT05071339
GnRH Antagonist Pre-treatment for the Prevention of Asynchronous Follicular Growth
Assaf-Harofeh Medical Center
INTERVENTIONAL
Updated Dec 15, 2025
Active Not Recruiting
PHASE3
NCT03767244
A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
Janssen Research & Development, LLC
INTERVENTIONAL
Updated Dec 15, 2025
Terminated
PHASE4
NCT05205837
A Randomized, Double-blinded, Clinical, Placebo-controlled Trial on the Effects of Therapy With Letrozole and hUman Choriongonadotropin in Male Hypogonadism Induced by Illicit Use of Anabolic Androgenic Steroids- The LUCAS Trial
Rigshospitalet, Denmark
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE3
NCT00116220
Study of External Beam Radiation Therapy With and Without Hormonal Therapy to Treat Prostate Cancer
Dana-Farber Cancer Institute
INTERVENTIONAL
Updated Dec 15, 2025
Terminated
PHASE2, PHASE3
NCT01603420
External Beam Radiation With or Without Chemotherapy to Treat High Risk Prostate Cancer
Proton Collaborative Group
INTERVENTIONAL
Updated Dec 15, 2025
Recruiting
PHASE1
NCT06162559
Neoadjuvant Trastuzumab, Pertuzumab and Tucatinib Without Chemotherapy in HER2-positive Breast Cancer: the TRAIN-4 Study
The Netherlands Cancer Institute
INTERVENTIONAL
Updated Dec 15, 2025
Unknown
PHASE2
NCT03373149
Growth Hormone Co-treatment Within a GnRH Antagonist Protocol in Patients With Poor Ovarian Response
Riyadh Fertility and Reproductive Health center
INTERVENTIONAL
Updated Dec 15, 2025
Unknown
NA
NCT01473459
Comparison Between Two Fertility Protocols in Obese Polycystic Ovary Syndrome Patients
Hillel Yaffe Medical Center
INTERVENTIONAL
Updated Dec 15, 2025
Recruiting
PHASE3
NCT06065748
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
Hoffmann-La Roche
INTERVENTIONAL
Updated Dec 15, 2025